The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 1, 2010, Pages 45-55

  Lin, Yong ^a   Bai, Lang ^a   Chen, Wenjie ^a   Xu, Shanling ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Cancer; Carcinogenesis; Chemoresistance; NF B; Prevention; Proliferation; Therapy

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; ACETYLSALICYLIC ACID; CARFILZOMIB; CARISOPRODOL; CEP 18770; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR; FLICE INHIBITORY PROTEIN; I KAPPA B ALPHA; I KAPPA B KINASE INHIBITOR; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; MLN 120B; MONOCYTE CHEMOTACTIC PROTEIN 1; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; PROTEASOME INHIBITOR; PROTEIN BCL 10; PROTEIN BCL XL; PROTEIN BNIP3; PROTEIN P53; RP 171; SALINOSPORAMIDE A; SC 514; SULINDAC; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS; DNA; I KAPPA B KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEASOME;

APOPTOSIS; CANCER IMMUNOLOGY; CANCER INVASION; CANCER PREVENTION; CANCER RESEARCH; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; INFLAMMATION; METASTASIS POTENTIAL; NONHUMAN; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; BIOSYNTHESIS; BIOTRANSFORMATION; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG EFFECT; GENE THERAPY; GENETICS; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOTRANSFORMATION; CELL TRANSFORMATION, NEOPLASTIC; DNA, NEOPLASM; GENE THERAPY; HUMANS; I-KAPPA B KINASE; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION;

EID: 72549111131     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903431069     Document Type: Review

References (100)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
2. Hayden MS, Ghosh S. Signaling to NF-kB. Genes Dev 2004;18(18):2195-2224
3. Devin A, Cook A, Lin Y, et al. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 2000;12(4):419-429
4. Yang J, Lin Y, Guo Z, et al. The essential role of MEKK3 in TNF-induced NF-kB activation. Nat Immunol 2001;2(7):620-624
5. Chen ZJ. Ubiquitin signalling in the NF-kB pathway. Nat Cell Biol 2005;7(8):758-765
6. Janssens S, Tinel A, Lippens S, Tschopp J. PIDD mediates NF-kB activation in response to DNA damage. Cell 2005;123(6):1079-1092
7. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007;14(3):400-410
8. Wu ZH, Mabb A, Miyamoto S. PIDD: a switch hitter. Cell 2005;123(6):980-982
9. Wu CJ, Conze DB, Li T, et al. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kB activation. Nat Cell Biol 2006;8(4):398-406
10. Zarnegar BJ, Wang Y, Mahoney DJ, et al. Noncanonical NF-kB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008;9(12):1371-1378
11. Kato T Jr, Delhase M, Hoffmann A, Karin M. CK2 Is a C-terminal IkB kinase responsible for NF-kB activation during the UV response. Mol Cell 2003;12(4):829-839
12. Tergaonkar V, Bottero V, Ikawa M, et al. IkB kinase-independent IkBa degradation pathway: functional NF-kB activity and implications for cancer therapy. Mol Cell Biol 2003;23(22):8070-8083
13. Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kB and IkB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005;30(1):43-52
14. Aggarwal BB. Nuclear factor-kB: the enemy within. Cancer Cell 2004;6(3):203-208
15. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-kB. Mol Cell 2004;13(6):853-865
16. Janssens S, Tschopp J. Signals from within: the DNA-damage-induced NF-kB response. Cell Death Differ 2006;13(5):773-784
17. Chen W, Wang X, Bai L, et al. Blockage of NF-kB by IKKb- or RelA-siRNA rather than the NF-kB super-suppressor IkBa mutant potentiates adriamycin-induced cytotoxicity in lung cancer cells. J Cell Biochem 2008;105(2):554-561
18. Hur GM, Lewis J, Yang Q, et al. The death domain kinase RIP has an essential role in DNA damage-induced NF-kB activation. Genes Dev 2003;17(7):873-882
19. Karin M, Greten FR. NF-kB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5(10):749-759
20. Ea CK, Deng L, Xia ZP, et al. Activation of IKK by TNFa requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 2006;22(2):245-257
21. Wang L, Du F, Wang X. TNF-a induces two distinct caspase-8 activation pathways. Cell 2008;133(4):693-703
22. Varfolomeev E, Goncharov T, Fedorova AV, et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor a (TNFa)-induced NF-kB activation. J Biol Chem 2008;283(36):24295-24299
23. Singh NP, Nagarkatti M, Nagarkatti PS. Role of dioxin response element and nuclear factor-kB motifs in 2,3,7,8-tetrachlorodibenzop- dioxin-mediated regulation of Fas and Fas ligand expression. Mol Pharmacol 2007;71(1):145-157
24. Shou Y, Li N, Li L, et al. NF-kB-mediated up-regulation of Bcl-XS and Bax contributes to cytochrome c release in cyanide-induced apoptosis. J Neurochem 2002;81(4):842-852
25. Wang P, Qiu W, Dudgeon C, et al. PUMA is directly activated by NF-kB andcontributes to TNF-a-induced apoptosis. Cell Death Differ 2009;16(9):1192-1202
26. Sarkar FH, Li Y. NF-kB: a potential target for cancer chemoprevention and therapy. Front Biosci 2008;13:2950-2959
27. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-kB, transformed phenotype, and survival of breast cancer cells. Cancer Res 2002;62(22):6770-6778
28. Mann AP, Verma A, Sethi G, et al. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kB in cancer cells: delineation of a novel pathway. Cancer Res 2006;66(17):8788-8795
29. Sun SC, Yamaoka S. Activation of NF-kB by HTLV-I and implications for cell transformation. Oncogene 2005;24(39):5952-5964
30. Tang H, Oishi N, Kaneko S, Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 2006;97(10):977-983
31. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3(9):745-756
32. Karin M. Nuclear factor-kB in cancer development and progression. Nature 2006;441(7092):431-436
33. Podechard N, Lecureur V, Le Ferrec E, et al. Interleukin-8 induction by the environmental contaminant benzo(a) pyrene is aryl hydrocarbon receptor-dependent and leads to lung inflammation. Toxicol Lett 2008;177(2):130-137
34. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000;248(3):171-183
35. Greten FR, Eckmann L, Greten TF, et al. IKKb links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118(3):285-296
36. Pikarsky E, Porat RM, Stein I, et al. NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431(7007):461-466
37. Ruland J, Duncan GS, Elia A, et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kB and neural tube closure. Cell 2001;104(1):33-42
38. Perkins ND. NF-kB: tumor promoter or suppressor? Trends Cell Biol 2004;14(2):64-69
39. Chen F, Castranova V. Nuclear factor-kB, an unappreciated tumor suppressor. Cancer Res 2007;67(23):11093-11098
40. Wang LC, Okitsu CY, Zandi E. Tumor necrosis factor a-dependent drug resistance to purine and pyrimidine analogues in human colon tumor cells mediated through IKK. J Biol Chem 2005;280(9):7634-7644
41. Kim BY, Gaynor RB, Song K, et al. Constitutive activation of NF-kB in Ki-ras-transformed prostate epithelial cells. Oncogene 2002;21(29):4490-4497
42. Hammerman PS, Fox CJ, Cinalli RM, et al. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kB activation. Cancer Res 2004;64(22):8341-8348
43. Hanson JL, Hawke NA, Kashatus D, Baldwin AS. The nuclear factor kB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res 2004;64(20):7248-7255
44. Anto RJ, Mukhopadhyay A, Shishodia S, et al. Cigarette smoke condensate activates nuclear transcription factor-kB through phosphorylation and degradation of IkBa: correlation with induction of cyclooxygenase-2. Carcinogenesis 2002;23(9):1511-1518
45. Rius J, Guma M, Schachtrup C, et al. NF-kB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1a. Nature 2008;453(7196):807-811
46. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117(7):927-939
47. Huber MA, Beug H, Wirth T. Epithelial- mesenchymal transition: NF-kB takes center stage. Cell Cycle 2004;3(12):1477-1480
48. Wang X, Belguise K, Kersual N, et al. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 2007;9(4):470-478
49. Kim A, Kim MJ, Yang Y, et al. Suppression of NF-kB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis 2009;30(6):927-936
50. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009;15(2):425-430
51. Schmidt D, Textor B, Pein OT, et al. Critical role for NF-kB-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J 2007;26(3):710-719
52. Sakamoto K, Maeda S, Hikiba Y, et al. Constitutive NF-kB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 2009;15(7):2248-2258
53. Chu CY, Cha ST, Lin WC, et al. Stromal cell-derived factor-1a (SDF-1a/ CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2-NF-kB/interleukin-6 pathway. Carcinogenesis 2009;30(2):205-213
54. Chan DA, Kawahara TL, Sutphin PD, et al. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009;15(6):527-538
55. Kisseleva T, Song L, Vorontchikhina M, et al. NF-kB regulation of endothelial cell function during LPS-induced toxemia and cancer. J Clin Invest 2006;116(11):2955-2963
56. Zhou M, Gu L, Zhu N, et al. Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene 2003;22(50):8137-8144
57. Aguilera C, Hoya-Arias R, Haegeman G, et al. Recruitment of IkBa to the hes1 promoter is associated with transcriptional repression. Proc Natl Acad Sci USA 2004;101(47):16537-16542
58. Tabruyn SP, Griffioen AW. A new role for NF-kB in angiogenesis inhibition. Cell Death Differ 2007;14(8):1393-1397
59. Baud V, Karin M. Is NF-kB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009;8(1):33-40
60. Ahmed KM, Li JJ. ATM-NF-kB connection as a target for tumor radiosensitization. Curr Cancer Drug Targets 2007;7(4):335-342
61. Kamata H, Honda S, Maeda S, et al. Reactive oxygen species promote TNFa-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005;120(5):649-6162.
62. Tang G, Minemoto Y, Dibling B, et al. Inhibition of JNK activation through NF-kB target genes. Nature 2001;414(6861):313-317
63. Tergaonkar V, Pando M, Vafa O, et al. p53 stabilization is decreased upon NFkB activation: a role for NFkB in acquisition of resistance to chemotherapy. Cancer Cell 2002;1(5):493-503
64. Yang PM, Huang WC, Lin YC, et al. Loss of IKKb activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis. J Cell Mol Med 2009: published online Feb 20 2009, doi: 10.1111/j.1582-4934.2009.00712. x
65. Cianfrocca R, Muscolini M, Marzano V, et al. RelA/NF-kB recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells. Cell Death Differ 2008;15(2):354-363
66. Dey A, Verma CS, Lane DP. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br J Cancer 2008;98(1):4-8
67. Ros JE, Schuetz JD, Geuken M, et al. Induction of Mdr1b expression by tumor necrosis factor-a in rat liver cells is independent of p53 but requires NF-kB signaling. Hepatology 2001;33(6):1425-1431
68. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-kB in p53-mediated programmed cell death. Nature 2000;404(6780):892-897
69. Ganapathi R, Vaziri SA, Tabata M, et al. Inhibition of NF-kB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons. Curr Pharm Des 2002;8(22):1945-1958
70. Lee CT, Seol JY, Lee SY, et al. The effect of adenovirus-IkBa transduction on the chemosensitivity of lung cancer cell line with resistance to cis-diamminedichloroplatinum(II) (cisplatin) and doxorubicin(adriamycin). Lung Cancer 2003;41(2):199-206
71. Dreyfus DH, Nagasawa M, Gelfand EW, Ghoda LY. Modulation of p53 activity by I-kBa: evidence suggesting a common phylogeny between NF-kB and p53 transcription factors. BMC Immunol 2005;6(1):12. Published online 21 June 2005, doi:10.1186/1471-2172-6-12 (Pubitemid 41418112)
72. Shen HM, Tergaonkar V. NFkB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009;14(4):348-363
73. Garcia MG, Alaniz L, Lopes EC, et al. Inhibition of NF-kB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 2005;29(12):1425-1434
74. Hideshima T, Chauhan D, Kiziltepe T, et al. Biologic sequelae of IkB kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 2009;113(21):5228-5236
75. Yang J, Amiri KI, Burke JR, et al. BMS-345541 targets inhibitor of kB kinase and induces apoptosis in melanoma: involvement of nuclear factor kB and mitochondria pathways. Clin Cancer Res 2006;12(3 Pt 1):950-960
76. Choo MK, Sakurai H, Kim DH, Saiki I. A ginseng saponin metabolite suppresses tumor necrosis factor-a-promoted metastasis by suppressing nuclear factor-kB signaling in murine colon cancer cells. Oncol Rep 2008;19(3):595-600
77. Ravaud A, Cerny T, Terret C, et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 2005;41(5):702-707
78. Dingli D, Rajkumar SV. Emerging therapies for multiple myeloma. Oncology (Williston Park) 2009;23(5):407-415
79. Gasparian AV, Guryanova OA, Chebotaev DV, et al. Targeting transcription factor NFkB: comparative analysis of proteasome and IKK inhibitors. Cell Cycle 2009;8(10):1559-1566
80. Cardoso F, Durbecq V, Laes JF, et al. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol Cancer Ther 2006;5(12):3042-3051
81. Sloss CM, Wang F, Liu R, et al. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res 2008;14(16):5116-5123
82. Lynch TJ, Fenton D, Hirsh V, et al. A randomized Phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2009;4(8):1002-1009
83. Mabuchi S, Ohmichi M, Nishio Y, et al. Inhibition of NFkB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004;279(22):23477-23485
84. Baron JA. Aspirin and NSAIDs for the prevention of colorectal cancer. Rec Results Cancer Res 2009;181:223-229
85. Bank A, Yu J, Zhang L. NSAIDs downregulate Bcl-X(L) and dissociate BAX and Bcl-X(L) to induce apoptosis in colon cancer cells. Nutr Cancer 2008;60: (Suppl 1):98-103
86. Nandakumar V, Singh T, Katiyar SK. Multi-targeted prevention and therapy of cancer by proanthocyanidins. Cancer Lett 2008;269(2):378-387
87. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 2006;72(11):1439-1452 (Pubitemid 44666744)
88. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kB activation: from bench to bedside. Exp Biol Med (Maywood) 2008;233(1):21-31
89. Ju W, Wang X, Shi H, et al. A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kB pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol 2007;71(5):1381-1388
90. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 2008;29(11):1275-1288
91. Lin Y, Shi R, Wang X, Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets 2008;8(7):634-646
92. Uetsuka H, Haisa M, Kimura M, et al. Inhibition of inducible NF-kB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 2003;289(1):27-35
93. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs 2005;10(1):137-149
94. Lewis J, Devin A, Miller A, et al. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), andblockage of tumor necrosis factor-induced nuclear factor-kB activation. J Biol Chem 2000;275(14):10519-10526
95. Wang X, Ju W, Renouard J, et al. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kB pathway. Cancer Res 2006;66(2):1089-1095
96. Wang X, Chen W, Lin Y. Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-kB and Akt pathways. Biochem Biophys Res Commun 2007;355(3):807-812
97. Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAP1 to induce TNFa-dependent apoptosis. Cell 2007;131(4):682-693
98. Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kB activation, and TNFa-dependent apoptosis. Cell 2007;131(4):669-681
99. Bai L, Chen W, Wang X, et al. IKKb-mediated nuclear factor-kB activation attenuates smac mimetic-induced apoptosis in cancer cells. Mol Cancer Ther 2009;8(6): 1636-1645
100. Bhandarkar SS, Arbiser JL. Curcumin as an inhibitor of angiogenesis. Adv Exp Med Biol 2007;595:185-195